Atricure reports third quarter 2025 financial results; raises financial outlook for 2025

Mason, ohio--(business wire)--atricure, inc. (nasdaq: atrc), a leading innovator in surgical treatments and therapies for atrial fibrillation (afib), left atrial appendage (laa) management and post-operative pain management, today announced third quarter 2025 financial results. “our third quarter results demonstrate strong execution and patient focus across the business. we are seeing continued positive traction with our most recent product launches, including our atriclip platform and cryosphe.
ATRC Ratings Summary
ATRC Quant Ranking